title: Workshop report on some new ideas about the treatment of systemic lupus erythematosus.
abstract: Our increased understanding of the pathogenesis of systemic lupus erythematosus is leading to new ideas about its therapy. In this session of the workshop the use of LJP 394 a B cell toleragen and the use of an anti-CD20 monoclonal antibody were discussed in some detail. Their rationale and early clinical results were reviewed; both have shown encouraging clinical and serological benefit. Definitive double-blind clinical trials are still, however, awaited. In addition, the intriguing notion of using a nasal instillation of a histone peptide was described and early work in an experimental model presented.
authors.affiliation: La Jolla Pharmaceuticals, San Diego, California, USA.
authors.forename: M
authors.initials: M
authors.lastname: Linnik
authors.forename: N A
authors.initials: NA
authors.lastname: Staines
authors.forename: J
authors.initials: J
authors.lastname: Berden
authors.forename: D A
authors.initials: DA
authors.lastname: Isenberg
mesh_terms: D000974:Antibodies, Antinuclear / Q000276:immunology; D006657:Histones / Q000276:immunology; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000628:therapy*
chemical_list: D000974:Antibodies, Antinuclear; D006657:Histones